

bs-1914R**[Primary Antibody]****BioSS**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

Thrombin heavy chain Rabbit pAb**— DATASHEET —**

Host: Rabbit	Isotype: IgG	Applications: IHC-P (1:100-500)
Clonality: Polyclonal		IHC-F (1:100-500)
GeneID: 2147	SWISS: P00734	IF (1:100-500)
Target: Thrombin heavy chain		Reactivity: Human, Mouse, Rat (predicted: Rabbit, Pig, Cow, Chicken, Fish, Horse)
Immunogen: KLH conjugated synthetic peptide derived from human Thrombin heavy chain: 551-622/622.		Predicted MW.: 28/68 kDa
Purification: affinity purified by Protein A		Subcellular Location: Cytoplasm
Concentration: 1mg/ml		
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
Background: Des-gamma carboxyprothrombin (DCP), also known as protein induced by vitamin K absence/antagonist-II (PIVKA-II), is an abnormal form of the coagulation protein, prothrombin. Normally, the prothrombin precursor undergoes post-translational carboxylation (addition of a carboxylic acid group) by gamma-glutamyl carboxylase in the liver prior to secretion into plasma. DCP/PIVKA-II may be detected in people with deficiency of vitamin K (due to poor nutrition or malabsorption) and in those taking warfarin or other medication that inhibits the action of vitamin K.		

— VALIDATION IMAGES —

Paraformaldehyde-fixed, paraffin embedded (mouse liver tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Thrombin heavy chain) Polyclonal Antibody, Unconjugated (bs-1914R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.

— SELECTED CITATIONS —

- **[IF=5.988]** He Wenju. et al. Forsythiaside B ameliorates coagulopathies in a rat model of sepsis through inhibition of the formation of PAD4-dependent neutrophil extracellular traps. FRONT PHARMACOL. 2022 Nov;0:4709 IHC ;Rat. 36408247
- **[IF=3.161]** Shavit Stein E et al. Thrombin Inhibition Reduces the Expression of Brain Inflammation Markers upon Systemic LPS Treatment. Neural Plast. 2018 Jun 19;2018:7692182. WB ;Mouse. 30018633

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.